Li Jianing, Li Shuo, Yu Ling, Wei Jin, Li Shuang, Tan Hongyu
Department of Anesthesiology, Peking University Cancer Hospital & Institute, Beijing, People's Republic of China.
J Pain Res. 2022 Jul 17;15:1995-2004. doi: 10.2147/JPR.S372845. eCollection 2022.
As an adipocyte-secreted hormone, resistin is linked to inflammation, insulin resistance and atherosclerosis. Currently, resistin is proposed as a novel biomarker for postoperative pain intensity. However, due to the various types of surgery and limited numbers of studies, previous conclusions should be validated. This study aimed to explore the effect of resistin polymorphism (rs3745367) on pain thresholds and sufentanil consumption in gastric cancer patients.
A total of 148 gastric cancer patients enrolled in this study had their pain thresholds measured before surgery. After the exclusion of 16 patients, the characteristics of demography and clinic, numerical rating scale (NRS) and sufentanil consumption of 132 patients were recorded. Rs3745367 of resistin was identified by Sanger sequencing. Multivariate linear regression analysis was performed for sufentanil consumption and mechanical pain threshold.
The distributions of the GG, AG, and AA genotypes of rs3745367 among the participants were 54 (40.9%), 65 (49.2%), and 13 (9.9%), respectively. The mechanical pain threshold (P=0.04) and postoperative sufentanil consumption in the 1st 24 h (P=0.03) were significantly different among GG, AG, and AA genotype carriers. There was no significant difference among the three genotypes for the heat pain threshold and cold pain threshold. Regarding the NRS, no statistically significant difference among the three different genotypes was found 24 h postoperatively.
Rs3745367 of resistin is associated with the mechanical pain threshold and postoperative sufentanil consumption in gastric cancer patients. Patients with the AA genotype of rs3745367 present an increased mechanical pain threshold and decreased postoperative sufentanil consumption.
抵抗素作为一种脂肪细胞分泌的激素，与炎症、胰岛素抵抗和动脉粥样硬化相关。目前，抵抗素被认为是术后疼痛强度的一种新型生物标志物。然而，由于手术类型多样且研究数量有限，之前的结论有待验证。本研究旨在探讨抵抗素基因多态性（rs3745367）对胃癌患者疼痛阈值和舒芬太尼用量的影响。
本研究共纳入148例胃癌患者，术前测量其疼痛阈值。排除16例患者后，记录132例患者的人口统计学和临床特征、数字评分量表（NRS）及舒芬太尼用量。通过桑格测序法鉴定抵抗素的rs3745367。对舒芬太尼用量和机械性疼痛阈值进行多变量线性回归分析。
参与者中rs3745367的GG、AG和AA基因型分布分别为54例（40.9%）、65例（49.2%）和13例（9.9%）。GG、AG和AA基因型携带者的机械性疼痛阈值（P = 0.04）和术后24小时内舒芬太尼用量（P = 0.03）存在显著差异。三种基因型的热痛阈值和冷痛阈值无显著差异。关于NRS，术后24小时三种不同基因型之间无统计学显著差异。
抵抗素的rs3745367与胃癌患者的机械性疼痛阈值和术后舒芬太尼用量相关。rs3745367的AA基因型患者机械性疼痛阈值升高，术后舒芬太尼用量降低。
